Storia in 3 fonti

Dr Reddy’s launches Bosutinib tablets in US market

Dr. Reddy’s launches Bosutinib tablets in the US, enhancing its oncology portfolio through collaboration with MSN Laboratories.

Raccontata da

thehindubusinessline.com

morningstar.com

thehindu.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

thehindubusinessline.comStai leggendo1 mese fa

Dr Reddy’s launches Bosutinib tablets in US market

Dr. Reddy’s launches Bosutinib tablets in the US, enhancing its oncology portfolio through collaboration with MSN Laboratories.

originale

thehindu.com1 mese fa

Dr. Reddy’s launches generic cancer drug Bosutinib in U.S.

Dr. Reddy's launches generic Bosutinib 400mg with 180-day U.S. exclusivity; brand equivalent (Bosulif) had $253.8M annual sales. The first-to-file advantage signals India's complex oncology capability and cost pressure on branded cancer therapies for healthcare portfolios.

Leggi questa versione →

Timeline cronologica

sabato 13 giugno 2026·thehindubusinessline.com
Dr Reddy’s launches Bosutinib tablets in US market
Dr. Reddy’s launches Bosutinib tablets in the US, enhancing its oncology portfolio through collaboration with MSN Laboratories.
sabato 13 giugno 2026·morningstar.com
Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States
Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States

Dr Reddy’s launches Bosutinib tablets in US market

Dr. Reddy’s launches generic cancer drug Bosutinib in U.S.

Timeline cronologica

Dr Reddy’s launches Bosutinib tablets in US market

Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States

Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of…

Dr. Reddy’s launches generic cancer drug Bosutinib in U.S.